Lanadelumab Pharmacovigilance Knowledge Assessment

It blocks histamine receptors and prevents mast-cell degranulation It suppresses all inflammatory cytokine production throughout the immune system It inhibits plasma kallikrein and thereby limits downstream bradykinin generation It directly neutralizes every circulating mediator that causes tissue swelling

Active substance only and the date the case was received Dose, route, administration dates, formulation, presentation, batch and administration setting Event preferred term, country and reporter profession only Patient initials, seriousness classification and MedDRA version only

A plausible mechanism is sufficient to establish causality A plausible mechanism is irrelevant if the event is serious A plausible mechanism strengthens a hypothesis, but timing, objective evidence, alternatives and outcome remain necessary A plausible mechanism overrides documented exposure problems

The delay is irrelevant because monoclonal antibodies have no persistent pharmacodynamic effects The event should be attributed conclusively to immunogenicity The delayed exposure is a potentially relevant contributor, but disease activity and alternative causes still require assessment The event automatically demonstrates a manufacturing defect

Recording the patient's treatment intent and attack history Documenting objective findings and serial clinical changes Coding only a generic symptom without phenotype, chronology or alternative-cause assessment Recording the acute treatment and clinical outcome

Lanadelumab is definitively causal because the event occurred during exposure The ACE-inhibitor is definitively causal without reviewing the case The case remains uncertain or may be more consistent with another cause until phenotype, timing and competing explanations are clarified The event should be excluded from pharmacovigilance because causality is uncertain

It eliminates the need to document the administration date It creates opportunities to assess injection-site reactions, home-administration issues, handling and batch traceability It proves that all adverse events are local rather than systemic It makes product presentation and device information clinically irrelevant

Injection date and product name only Reaction appearance, injection site, technique, timing, vital signs, treatment, batch and outcome The patient's history of unrelated infections without exposure details A preferred-term count from the safety database without source documentation

Conclude that the new device causes hereditary angioedema attacks Ignore the change because the active substance is unchanged Assess presentation-specific exposure, administration technique, batch and quality information, while comparing clinical phenotypes and appropriate denominators Pool the reports with all historical swelling events without stratification

Classify it immediately as a hereditary angioedema attack because abdominal symptoms are typical Classify it immediately as drug toxicity because it occurred during treatment Obtain pain chronology, imaging and laboratory findings, acute treatment, outcome and assessment of alternative abdominal diagnoses Close the case if no injection-site reaction was reported